NRG1: An Emerging Tumor Agnostic Target

Download All

Gain expert insight into the emerging role of NRG1 fusions as rare oncogenic drivers in a variety of solid tumors and learn about the targeted therapies in development from expert commentaries, a text-based module, and a downloadable slideset.

person default
Maria E. Arcila, MD

ClinicalThought

Read this commentary from Maria E. Arcila, MD, on the recommendations for testing for NRG1 fusions in patients with solid tumors.

person default Maria E. Arcila, MD Released: November 16, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

In partnership with
Supported by an educational grant from
Elevation Oncology, Inc.

Clinical Care Options (CCO): expert opinions from Drs Stephen Liu, Maria Arcila, Dr. Ryma Benayed on testing and targeting NRG1 fusions

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue